Sionna scraps genetic disorder drug program after trial setback; shares tank | Reuters

Sionna Therapeutics halts cystic fibrosis drug development after trial failure

Sionna Therapeutics discontinued development of its experimental cystic fibrosis pill after it failed to show meaningful benefit when added to standard treatment in a mid-stage trial, causing shares to plunge.